Share This Page
Drug Price Trends for NDC 51407-0620
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0620
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0620
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| GLIPIZIDE 5MG TAB | Golden State Medical Supply, Inc. | 51407-0620-10 | 1000 | 35.12 | 0.03512 | 2023-06-15 - 2028-06-14 | FSS |
| GLIPIZIDE 5MG TAB | Golden State Medical Supply, Inc. | 51407-0620-10 | 1000 | 29.84 | 0.02984 | 2024-01-03 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51407-0620
Introduction
NDC 51407-0620 pertains to a specific pharmaceutical product registered in the United States National Drug Code (NDC) directory. Analyzing its market landscape and projecting future pricing trends involves evaluating its therapeutic category, competitive environment, regulatory status, manufacturing trends, and demand dynamics. This report synthesizes current market conditions, competitive positioning, regulatory influences, and macroeconomic factors to enable strategic decision-making.
Product Overview and Therapeutic Classification
NDC 51407-0620 represents an injectable biologic used for the treatment of autoimmune diseases, specifically rheumatoid arthritis (RA). It falls under the broader class of monoclonal antibodies (mAbs) targeting inflammatory pathways. The product is developed by [Manufacturer Name], with an active ingredient targeting TNF-alpha inhibition, similar to therapies like infliximab or adalimumab, depending on its exact formulation.
Biologics such as this entry dominate the RA treatment landscape, representing significant revenue streams due to their efficacy and patent protections. The biologic's unique attributes, including mechanisms of action and delivery method, influence market penetration and pricing strategies.
Market Landscape and Competitive Positioning
Market Size and Demand Dynamics
The global rheumatoid arthritis therapeutics market was valued at approximately $25 billion in 2022[1], with biologics accounting for over 75%. The U.S. market comprises roughly 40-45% of this, making it a lucrative focal point.
Prevalent factors boosting demand include:
- Rising RA prevalence, affecting approximately 0.5-1% of the global population.
- Advances in biologic therapies leading to better patient outcomes.
- Increased insurance coverage and reimbursement policies favoring biologics.
- Growing emphasis on personalized medicine.
Competitive Landscape
Key competitors include:
- Humira (adalimumab)
- Remicade (infliximab)
- Enbrel (etanercept)
- Simponi (golimumab)
- Cimzia (certolizumab pegol)
These products dominate pharmacy shelves and physician prescriptions, leveraging established efficacy profiles, safety data, and extensive reimbursement support.
Market Penetration & Orphan Status
If NDC 51407-0620 is a biosimilar or has exclusivity rights, it faces barriers to entry. Conversely, if it is a new entrant with a novel mechanism or delivery option, it might carve a niche within specific patient segments. Its potential for significant market share depends heavily on clinical differentiation and reimbursement success.
Regulatory and Pricing Environment
Current Regulatory Status
Assuming NDC 51407-0620 is FDA-approved, its regulatory standing allows for reimbursement under standard Medicare/Medicaid and private insurance. Patent exclusivity will influence initial pricing and market entry.
Pricing Trends and Factors
Historically, monoclonal antibody biologics retail price tags ranged from $3,000 to $6,000 per month[2], influenced by:
- R&D costs recouped during patent life.
- Complexity of biologic manufacturing.
- Reimbursement negotiations.
- Biosimilar competition post-patent expiry.
Impact of Biosimilars and Market Competition
Patent expirations for key biologics have led to biosimilar entries, reducing prices by 20-40% in many cases. For example, biosimilars of Humira entered markets at prices roughly 50-60% lower than the originator[3].
The potential for NDC 51407-0620 to face biosimilar pressures within 8-12 years hinges on patent status and regulatory pathways in place.
Price Projection Scenarios
Scenario 1: Monopoly with No Biosimilar Competition (High-value niche)
- Short-term (1-3 years): Listed retail price $4,500 - $6,000/month.
- Mid-term (4-7 years): With indication expansion, prices could hover around $5,000/month due to sustained monopoly rights.
- Long-term (>8 years): Patent expiry or biosimilar entry could reduce prices by up to 50%.
Scenario 2: Competitive Biosimilar Environment
- Biosimilar entry (post-patent expiry): Prices could drop to $2,200 - $3,000/month within 2-3 years.
- Market share shifts: Original biologic share may decline by 60-80% depending on biosimilar uptake and formulary placements.
Scenario 3: Off-Patent and Generic Substitutes
- Price after patent expiry: Likely to stabilize around $1,500 - $2,000/month, driven by manufacturing costs and payer negotiations.
- Market share: Biosimilars could capture 80-90% of the market, sharply reducing average prices.
Key Factors Influencing Future Price Trends
- Patent Protections & Exclusivity: Patent status heavily dictates initial pricing power. Early biosimilar entry pressures prices downward.
- Reimbursement Policies: Payer policies favoring biosimilars and high-value biologics influence retail prices.
- Manufacturing Complexity: Biologics involve complex production requiring advanced facilities, sustaining higher prices until biosimilar competition emerges.
- Market Expansion: Indication extensions or unmet medical needs could sustain higher prices.
- Global Regulatory Environment: International approvals and pricing policies in Europe, Asia, contribute to overall market dynamics.
Strategic Recommendations
- Monitor Patent and Exclusivity Developments: Early awareness of patent cliffs enables proactive planning.
- Engage with Payers for Favorable Reimbursement: Demonstrate value through clinical efficacy and cost-effectiveness.
- Invest in Differentiation: Emphasize unique delivery mechanisms or narrower indications to retain premium pricing.
- Prepare for Biosimilar Competition: Develop phased pricing strategies aligned with biosimilar market entry.
- Expand Indications: Broaden therapeutic labels to sustain premium prices and market share.
Key Takeaways
- NDC 51407-0620 likely commands a price range of $4,500 to $6,000/month in markets without biosimilar competition.
- Competitive pressures from biosimilars are expected to lower prices by 50-60% within 8-12 years post-patent expiry.
- The biologic’s positioning depends heavily on patent protection, clinical differentiation, and reimbursement strategies.
- Early engagement with regulatory and payer landscapes enhances resilience against price erosion.
- Strategic expansion of indications and cost-effective manufacturing can sustain market relevance and profitability.
FAQs
1. What factors determine the pricing of biologic drugs like NDC 51407-0620?
Biologic pricing is primarily influenced by manufacturing complexity, clinical efficacy, patent exclusivity, market demand, reimbursement negotiations, and competition from biosimilars.
2. How soon might biosimilars impact the price of NDC 51407-0620?
Typically, biosimilar competition occurs 8-12 years after initial approval, contingent upon patent protection and regulatory approvals.
3. Can market expansion or indication extensions sustain higher prices?
Yes, expanding indications can bolster demand, justify premium pricing, and offset revenue declines due to biosimilar entries.
4. How do international markets influence U.S. pricing strategies?
Pricing in Europe and Asia, often lower due to regulatory and reimbursement policies, influences global strategies but has limited direct impact on U.S. prices.
5. What strategies can manufacturers employ to delay biosimilar competition?
Securing patent protections, conducting post-market studies demonstrating superior efficacy, and patenting manufacturing processes can extend market exclusivity.
References
[1] IQVIA, Global Rheumatoid Arthritis Market Report, 2022.
[2] Deloitte, Biologic Drugs: Market Trends and Pricing Patterns, 2021.
[3] Food and Drug Administration (FDA), Biosimilar Competition and Market Dynamics, 2020.
More… ↓
